PBRM1 and neoplasm: It should be noted that in a previous publication, Liu et al. [61] analyzed 3 independent patient cohorts and murine pre-clinical models to demonstrate that the loss of PBRM1 is associated with a lesser immunogenic tumor microenvironment (decreased immune infiltrates), and consequently to resistance to ICI (anti-PD-1 treatment).